Pharma M&A Briefing: AstraZeneca rejects Pfizer

AstraZeneca rejects Pfizer’s new proposal

Pfizer increased its offer to AstraZeneca to £50 a share today, putting pressure on the UK pharmaceuticals group to open discussions, in what could lead to a deal that would create the world’s largest drugs company. However within hours AstraZeneca has once again refused to come to the table. In a statement released today, AstraZeneca have stated that the terms outlined …

Pharma M&A Forecast Sunny

Sunny with little chance of rain: Pharma M&A forecast

Pharma M&A activity is hot out the blocks for the first quarter, with activity in the Pharma, Medical & Biotech sector totaling $63.4 billion, higher than its 2013 counterpart at $14.2 billion.   On 9th April Mergermarket released its Global Q1 2014  Pharma, Medical & Biotech M&A Trend Report,  identifying large scale growth in the pharmaceutical sector, compared to last year. …